Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Aurora Investment Counsel purchased 18,233 Halozyme shares worth approximately $1.43 million during the second quarter. Institutional investors collectively own 97.79% of the company.
• Halozyme reported strong quarterly results, with EPS of $2.28 beating estimates of $1.79 and revenue rising 47.7% year over year to $481 million. The company provided fiscal 2026 EPS guidance of $8.65–$9.00.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $91.20 target price, while the stock opened at $107.62. Insiders sold 64,103 shares worth $5.23 million in the last quarter under pre-arranged trading plans.

Aurora Investment Counsel purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 18,233 shares of the biopharmaceutical company's stock, valued at approximately $1,427,000.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Measured Wealth Private Client Group LLC grew its stake in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC raised its position in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 343 shares during the period. MidFirst Bank bought a new stake in Halozyme Therapeutics in the second quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $28,000. Finally, Harbour Investments Inc. boosted its position in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 372 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Buying and Selling

In other news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company's stock, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on HALO shares. Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. TD Cowen raised their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Weiss Ratings cut shares of Halozyme Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, August 14th. Finally, Citizens Jmp boosted their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research note on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $91.20.

Halozyme Therapeutics Stock Up 2.6%

HALO opened at $107.62 on Thursday. The firm has a market cap of $12.21 billion, a price-to-earnings ratio of 32.13, a PEG ratio of 0.42 and a beta of 0.85. The firm's 50-day simple moving average is $81.71 and its 200-day simple moving average is $73.26. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $107.96.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business's revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source